DIA/FDA Co-sponsored Conference Discusses Use of (Q)SAR to Assess Impurities for Potential Genotoxicity

Share Article

Find out what constitutes an acceptable in silico evaluation and how to incorporate public and proprietary sources of data into an integrated assessment.

Logo

The timing of this particular workshop will provide critical input on the discussions for the June 2011 meeting for ICH M7 (Mutagenic Impurities).

DIA and FDA will host the DIA/FDA Quantitative Structure-activity Relationship (Q)SAR Approaches to Assessing Genotoxic Impurities in Pharmaceuticals Conference on April 7, 2011 in Rockville, MD.

Industry scientists and regulators will address what constitutes an acceptable in silico evaluation and how to incorporate public and proprietary sources of data into an integrated assessment. The timing of this particular workshop will provide critical input on the discussions for the June 2011 meeting for ICH M7 (Mutagenic Impurities). Session topics include:

  • Strategies for Classifying and Controlling Potentially Genotoxic Impurities in the Pharmaceutical Industry
  • Regulatory Perspectives: FDA, EU, and Japan
  • What Current (Q)SAR Computational Models Can Tell Us about Ames Predictivity
  • Industry Use of (Q)SAR: Overview and Case Studies
  • Integration of (Q)SAR into Hazard Identification: Role of ICH

Dr. David Jacobson-Kram, Associate Director of Pharmacology and Toxicology, Office of New Drugs (OND), CDER, FDA, will deliver the keynote address titled: “Use of in Silico Analyses for Mutagenicity Predictions: State-of-the-Art and Regulatory Implications.”

Since 1976, Dr. Jacobson-Kram has published more than 80 abstracts, 60 peer-reviewed articles, and 30 review articles or book chapters. The majority of these publications deal which methods and issues in genetic and molecular toxicology.

Register for DIA/FDA Quantitative Structure-activity Relationship (Q)SAR Approaches to Assessing Genotoxic Impurities in Pharmaceuticals

ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joe Krasowski
Visit website